Evaluating the use of Uromune® autovaccine in recurrent urinary tract infections: a pilot unicenter retrospective study in Reus, Spain

  • Published on 01/31/2025
  •  Reading time: 6 min.

Iftimie Simona 1, Ladero-Palacio Paula 1, López-Azcona Ana F. 1, Pujol-Galarza Laia 2, Pont-Salvadó Antoni 2, Gabaldó-Barrios Xavier 3, Joven Jorge 4, Camps Jordi 4, Castro Antoni 1, Pascual-Queralt Mercè 2

1 https://ror.org/04f7pyb58 Research Group on Autoimmunity, Infection and Thrombosis (GRAIIT), Department of Internal Medicine Hospital Universitari de Sant Joan, Institut d’Investigació Sanitària Pere Virgili, Universitat Rovira i Virgili Reus Spain
2 https://ror.org/04f7pyb58 Department of Urology Hospital Universitari de Sant Joan, Institut d’Investigació Sanitària Pere Virgili, Universitat Rovira i Virgili Reus Spain
3 https://ror.org/04f7pyb58 Department of Clinical Laboratory Hospital Universitari de Sant Joan, Institut d’Investigació Sanitària Pere Virgili, Universitat Rovira i Virgili Reus Spain
4 https://ror.org/04f7pyb58 Unitat de Recerca Biomèdica Hospital Universitari de Sant Joan, Institut d’Investigació Sanitària Pere Virgili, Universitat Rovira i Virgili Reus Spain

Abstract

Background Urinary tract infections (UTIs) are a significant global health issue, especially among women, with growing concerns related to antibiotic resistance and adverse effects. The Uromune®, a sublingual, heat-inactivated, polybacterial vaccine, represents a promising therapeutic alternative by enhancing immune responses against uropathogens.
Methods This pilot retrospective study, conducted at Hospital Universitari de Sant Joan de Reus...

ContentGeneMD

To continue reading this article in Full-Text...

* Access is totally free, without commitment or condition. Service exclusively reserved for healthcare professionals.

Peer-Reviewed Journals A-Z

Search | Advanced search

Get the latest news in Urology

Receive our newsletter to stay up to date with the latest news in Urology